Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
Patients with autoimmune diseases are among the susceptible groups to COVID-19 infection because of the complexity of their conditions and the side effects of the immunosuppressive drugs used to treat them. They might show impaired immunogenicity to COVID-19 vaccines and have a higher risk of develo...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/9/1456 |
| _version_ | 1797576475402043392 |
|---|---|
| author | Alvina Widhani Anshari Saifuddin Hasibuan Retia Rismawati Suzy Maria Sukamto Koesnoe Muhammad Ikrar Hermanadi Youdiil Ophinni Chika Yamada Kuntjoro Harimurti Aldean Nadhyia Laela Sari Evy Yunihastuti Samsuridjal Djauzi |
| author_facet | Alvina Widhani Anshari Saifuddin Hasibuan Retia Rismawati Suzy Maria Sukamto Koesnoe Muhammad Ikrar Hermanadi Youdiil Ophinni Chika Yamada Kuntjoro Harimurti Aldean Nadhyia Laela Sari Evy Yunihastuti Samsuridjal Djauzi |
| author_sort | Alvina Widhani |
| collection | DOAJ |
| description | Patients with autoimmune diseases are among the susceptible groups to COVID-19 infection because of the complexity of their conditions and the side effects of the immunosuppressive drugs used to treat them. They might show impaired immunogenicity to COVID-19 vaccines and have a higher risk of developing COVID-19. Using a systematic review and meta-analysis, this research sought to summarize the evidence on COVID-19 vaccine efficacy, immunogenicity, and safety in patients with autoimmune diseases following predefined eligibility criteria. Research articles were obtained from an initial search up to 26 September 2022 from PubMed, Embase, EBSCOhost, ProQuest, MedRxiv, bioRxiv, SSRN, EuroPMC, and the Cochrane Center of Randomized Controlled Trials (CCRCT). Of 76 eligible studies obtained, 29, 54, and 38 studies were included in systematic reviews of efficacy, immunogenicity, and safety, respectively, and 6, 18, and 4 studies were included in meta-analyses for efficacy, immunogenicity, and safety, respectively. From the meta-analyses, patients with autoimmune diseases showed more frequent breakthrough COVID-19 infections and lower total antibody (TAb) titers, IgG seroconversion, and neutralizing antibodies after inactivated COVID-19 vaccination compared with healthy controls. They also had more local and systemic adverse events after the first dose of inactivated vaccination compared with healthy controls. After COVID-19 mRNA vaccination, patients with autoimmune diseases had lower TAb titers and IgG seroconversion compared with healthy controls. |
| first_indexed | 2024-03-10T21:52:28Z |
| format | Article |
| id | doaj.art-53da12be95544fe582b5a0abff0d2785 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T21:52:28Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-53da12be95544fe582b5a0abff0d27852023-11-19T13:19:13ZengMDPI AGVaccines2076-393X2023-09-01119145610.3390/vaccines11091456Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-AnalysisAlvina Widhani0Anshari Saifuddin Hasibuan1Retia Rismawati2Suzy Maria3Sukamto Koesnoe4Muhammad Ikrar Hermanadi5Youdiil Ophinni6Chika Yamada7Kuntjoro Harimurti8Aldean Nadhyia Laela Sari9Evy Yunihastuti10Samsuridjal Djauzi11Allergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, IndonesiaAllergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, IndonesiaAllergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, IndonesiaAllergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, IndonesiaAllergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, IndonesiaAllergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, IndonesiaDivision of Clinical Virology, Center for Infectious Diseases, Graduate School of Medicine, Kobe University, Kobe 650-0017, JapanCenter for Southeast Asian Studies, Kyoto University, Kyoto 606-8304, JapanGeriatric Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, IndonesiaAllergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, IndonesiaAllergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, IndonesiaAllergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta 10430, IndonesiaPatients with autoimmune diseases are among the susceptible groups to COVID-19 infection because of the complexity of their conditions and the side effects of the immunosuppressive drugs used to treat them. They might show impaired immunogenicity to COVID-19 vaccines and have a higher risk of developing COVID-19. Using a systematic review and meta-analysis, this research sought to summarize the evidence on COVID-19 vaccine efficacy, immunogenicity, and safety in patients with autoimmune diseases following predefined eligibility criteria. Research articles were obtained from an initial search up to 26 September 2022 from PubMed, Embase, EBSCOhost, ProQuest, MedRxiv, bioRxiv, SSRN, EuroPMC, and the Cochrane Center of Randomized Controlled Trials (CCRCT). Of 76 eligible studies obtained, 29, 54, and 38 studies were included in systematic reviews of efficacy, immunogenicity, and safety, respectively, and 6, 18, and 4 studies were included in meta-analyses for efficacy, immunogenicity, and safety, respectively. From the meta-analyses, patients with autoimmune diseases showed more frequent breakthrough COVID-19 infections and lower total antibody (TAb) titers, IgG seroconversion, and neutralizing antibodies after inactivated COVID-19 vaccination compared with healthy controls. They also had more local and systemic adverse events after the first dose of inactivated vaccination compared with healthy controls. After COVID-19 mRNA vaccination, patients with autoimmune diseases had lower TAb titers and IgG seroconversion compared with healthy controls.https://www.mdpi.com/2076-393X/11/9/1456autoimmuneefficacyimmunogenicitysafetyvaccineCOVID-19 |
| spellingShingle | Alvina Widhani Anshari Saifuddin Hasibuan Retia Rismawati Suzy Maria Sukamto Koesnoe Muhammad Ikrar Hermanadi Youdiil Ophinni Chika Yamada Kuntjoro Harimurti Aldean Nadhyia Laela Sari Evy Yunihastuti Samsuridjal Djauzi Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis Vaccines autoimmune efficacy immunogenicity safety vaccine COVID-19 |
| title | Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis |
| title_full | Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis |
| title_fullStr | Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis |
| title_short | Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis |
| title_sort | efficacy immunogenicity and safety of covid 19 vaccines in patients with autoimmune diseases a systematic review and meta analysis |
| topic | autoimmune efficacy immunogenicity safety vaccine COVID-19 |
| url | https://www.mdpi.com/2076-393X/11/9/1456 |
| work_keys_str_mv | AT alvinawidhani efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT ansharisaifuddinhasibuan efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT retiarismawati efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT suzymaria efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT sukamtokoesnoe efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT muhammadikrarhermanadi efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT youdiilophinni efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT chikayamada efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT kuntjoroharimurti efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT aldeannadhyialaelasari efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT evyyunihastuti efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis AT samsuridjaldjauzi efficacyimmunogenicityandsafetyofcovid19vaccinesinpatientswithautoimmunediseasesasystematicreviewandmetaanalysis |